Clean Cells Acquires Anaquant: Building an End-to-End Analytical Platform from Early Development Through GMP Release

For biopharma developers, the deal creates something the European CRO market has lacked: a single partner capable of supporting a biologic asset from early-stage discovery analytics all the way through GMP-grade regulatory release testing, with proprietary analytical tools underpinning every stage .

Why Clean Cells Acquired Anaquant

Clean Cells, a member of the Clean Biologics Group backed by ARCHIMED, built its reputation on late-stage and GMP-grade quality control — biosafety testing, cell banking, viral clearance, sterility, mycoplasma testing, and lot-release documentation . Its historical strength was in the final stretch of drug development.

The acquisition of Anaquant fills the gap at the front end. Anaquant brings more than 15 years of experience developing standardized, accessible mass spectrometry methods for protein characterization, covering identity testing, impurity quantification, and post-translational modification analysis . The combined platform now covers the full analytical lifecycle .

Three Strategic Benefits

Vertical Integration and a Unified Provider

Before the acquisition, biopharma developers typically split early-stage discovery analytics and GMP release testing across separate CROs, creating handoff risks, documentation inconsistencies, and delays . Clean Cells can now offer both from a single organization, with a unified quality management system and regulatory-compliant documentation from day one .

Expanded Client Lifecycle Coverage

The deal bridges a critical gap. Clean Cells' historical strength was in late-stage and GMP-grade QC. Anaquant's mass spectrometry capabilities extend the combined offering into early-stage biopharmaceutical development — protein characterization, early PK/PD studies, and host cell protein (HCP) profiling — enabling seamless handoffs from discovery support through to regulatory submission .

Competitive Differentiation in the European CRO Market

By adding proprietary MS-based HCP analysis and protein characterization tools, Clean Cells differentiates itself from other QC-only CROs. Having a proprietary technology (ReadyBeads™) and validated kits in-house creates a defensible technical advantage that is difficult for competitors to replicate .

Expanded Capabilities from the Acquisition

Mass-Spectrometry-Based Protein Characterization

Anaquant brings deep expertise in protein quantification and identification via mass spectrometry, including post-translational modification analysis, drug-target quantification, and monitoring of protein expression in gene and cell therapy products . These capabilities were previously offered as standalone services by Anaquant — early PK/PD studies, specific and global HCP analysis, and protein characterization — and can now be bundled with Clean Cells' existing cell-line testing, viral clearance, and biosafety portfolios .

Patented ReadyBeads™ HCP Profiling Technology

The most distinctive piece of the acquisition is ReadyBeads™, a proprietary technology for host cell protein analysis. ReadyBeads™ are water-soluble biopolymer beads pre-adsorbed with known quantities of proteotypic peptides . They dissolve directly in the sample, releasing internal standards that co-process with the analyte from the very first step, solving reproducibility and stability issues common with low-concentration peptide mixtures .

Anaquant's HCPprofiler Kit is the first validated kit for HCP quantification using mass spectrometry. It features 54 proteotypic peptides adsorbed onto ReadyBeads to create a universal internal calibration curve, along with dedicated software that converts MS signal into protein amount . The kit uses the TOP3 approach to convert MS signal of each identified HCP into parts per million (ppm) or ng/ml .

This technology enables clients to shift from traditional ELISA-based HCP testing to a mass-spectrometry workflow that is faster, more reproducible, and capable of both quantifying total HCP burden and identifying specific HCP species — critical for immunogenicity risk assessment . As a representative put it, "If you can put sugar in coffee, you can use our technology" .

The End-to-End Analytical Platform

The combined platform now spans the entire biopharmaceutical development timeline:

The result is a single CRO partner that can support a biologic asset from early discovery analytics all the way to regulatory-ready GMP release testing, with proprietary tools — ReadyBeads™ — and validated MS workflows underpinning the analytical rigor at every stage .

The Bottom Line

For biopharma developers working on monoclonal antibodies, gene therapies, and other complex biologics, the Clean Cells–Anaquant combination eliminates a fragmentation that has long complicated analytical development and QC release. Developers now have a single CRO with the mass spectrometry depth for early characterization and the regulatory infrastructure for GMP release — backed by a proprietary bead technology that improves reproducibility in HCP analysis. The acquisition positions Clean Cells as one of the few European CROs with truly end-to-end analytical capabilities, and the first to offer a validated MS-based HCP kit as part of a broader QC platform .